Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Preferred Stock Liabilities (2018 - 2019)

10x Genomics (TXG) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $243.2 million as the latest value for Q2 2019.

  • Quarterly Preferred Stock Liabilities changed N/A to $243.2 million in Q2 2019 from the year-ago period, while the trailing twelve-month figure was $243.2 million through Jun 2019, changed N/A year-over-year, with the annual reading at $243.2 million for FY2018, 53.55% up from the prior year.
  • Preferred Stock Liabilities hit $243.2 million in Q2 2019 for 10x Genomics, roughly flat from $243.2 million in the prior quarter.
  • In the past five years, Preferred Stock Liabilities ranged from a high of $243.2 million in Q4 2018 to a low of $208.3 million in Q3 2018.